ES8305212A1 - Procedimiento de obtencion de composiciones antiateroscleroticas. - Google Patents

Procedimiento de obtencion de composiciones antiateroscleroticas.

Info

Publication number
ES8305212A1
ES8305212A1 ES513964A ES513964A ES8305212A1 ES 8305212 A1 ES8305212 A1 ES 8305212A1 ES 513964 A ES513964 A ES 513964A ES 513964 A ES513964 A ES 513964A ES 8305212 A1 ES8305212 A1 ES 8305212A1
Authority
ES
Spain
Prior art keywords
hexadecylamino
cyclodextrin
benzoic acid
inclusion compound
matter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES513964A
Other languages
English (en)
Other versions
ES513964A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of ES8305212A1 publication Critical patent/ES8305212A1/es
Publication of ES513964A0 publication Critical patent/ES513964A0/es
Granted legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

PROCEDIMIENTO PARA LA OBTENCION DE COMPOSICIONES ANTIARTERIOSCLEROTICAS A BASE DE UN COMPUESTO DE INCLUSION QUE COMPRENDE SAL SODICA DE ACIDO P-HEXADECILAMINO BENZOICO EN BETA-CICLODEXTRINA. CONSISTE EN PONER EN CONTACTO, EN UNA PRIMERA ETAPA, UNA SAL SODICA DE ACIDO P-HEXADECILAMINO BENZOICO CON BETA-CICLODEXTRINA, PARA OBTENER UN COMPUESTO DE INCLUSION QUE CONTIENE APROXIMADAMENTE UN 8% DE SAL SODICA DE ACIDO P-HEXADECILAMINO BENZOICO EN BETA-CICLODEXTRINA. EN UNA SEGUNDA ETAPA, EL COMPUESTO OBTENIDO EN LA PRIMERA ETAPA, SE PONE EN CONTACTO CON UN PORTADOR FARMACEUTICAMENTE ACEPTABLE. DE APLICACION EN LA TERAPIA DE ARTERIOSCLEROSIS.
ES513964A 1981-07-16 1982-07-14 Procedimiento de obtencion de composiciones antiateroscleroticas. Granted ES513964A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/283,852 US4407795A (en) 1981-07-16 1981-07-16 Inclusion compound of p-hexadecylamino benzoic acid in cyclodextrin and method of use

Publications (2)

Publication Number Publication Date
ES8305212A1 true ES8305212A1 (es) 1983-04-16
ES513964A0 ES513964A0 (es) 1983-04-16

Family

ID=23087838

Family Applications (1)

Application Number Title Priority Date Filing Date
ES513964A Granted ES513964A0 (es) 1981-07-16 1982-07-14 Procedimiento de obtencion de composiciones antiateroscleroticas.

Country Status (11)

Country Link
US (1) US4407795A (es)
EP (1) EP0070368A1 (es)
JP (1) JPS5818342A (es)
AU (1) AU8605082A (es)
DK (1) DK318982A (es)
ES (1) ES513964A0 (es)
GR (1) GR76175B (es)
IL (1) IL65818A0 (es)
PL (1) PL237497A1 (es)
PT (1) PT75254B (es)
ZA (1) ZA825069B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU183430B (en) * 1981-05-12 1984-05-28 Chinoin Gyogyszer Es Vegyeszet Process for producing cyclodextrine inclusion complexes of n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine or n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine-hydrochloride
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
EP0094157B1 (en) * 1982-04-30 1987-07-29 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its use
JPS5920230A (ja) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤
HU190818B (en) * 1982-11-09 1986-11-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for producing complexes of piperonyl-butoxide-cyclodextrin
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
JPS6025967A (ja) * 1983-07-21 1985-02-08 Eisai Co Ltd トリパミド包接化合物
US4732915A (en) * 1983-11-02 1988-03-22 Alza Corporation Process for increasing solubility of drug
JPS6140298A (ja) * 1984-06-30 1986-02-26 Zeria Shinyaku Kogyo Kk シクロアルテノ−ルフエルラ酸エステル−シクロデキストリン複合体
US4865850A (en) * 1986-09-08 1989-09-12 See/Shell Biotechnology, Inc. Dietary fat reduction
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5153166A (en) * 1988-08-18 1992-10-06 Trustees Of At Biochem Chromatographic stationary supports
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5091192A (en) * 1990-01-16 1992-02-25 Natur-All Systems, Inc. Bile salts permanently bound to insoluble cellulose as a dietary supplement
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5746223A (en) * 1996-10-11 1998-05-05 Williams; Kevin Jon Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
US5942501A (en) * 1996-08-16 1999-08-24 Collaborative Laboratories, Inc. Cyclodextrin derivative complex
FR2823207B1 (fr) * 2001-04-10 2004-12-03 Pf Medicament Complexes d'anilides a chaine polycarbonee et de cyclodestrines, leur preparation et leur application en tant que medicamment en particulier pour le traitement des dislipidemies
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010466A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070009532A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
EP2968126B1 (en) * 2013-03-15 2022-04-06 The Board of Regents of The University of Texas System Liquids rich in noble gas and methods of their preparation and use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472835A (en) * 1964-02-12 1969-10-14 American Mach & Foundry Schardinger dextrins
US3453257A (en) * 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3459732A (en) * 1967-03-22 1969-08-05 Corn Products Co Cyclodextrin carbamates
US3453260A (en) * 1967-03-22 1969-07-01 Corn Products Co Cyclic anhydride esters of cyclodextrin
US4066829A (en) * 1976-07-12 1978-01-03 American Cyanamid Company Malto-dextrin poly(H-)sulfates
US4100342A (en) * 1976-08-09 1978-07-11 Fmc Corporation Process of producing dextrin carboxylates
ZA784196B (en) * 1977-08-26 1979-07-25 American Cyanamid Co Method of treating atherosclerosis
US4311694A (en) * 1979-12-31 1982-01-19 American Cyanamid Company Amorphous coprecipitates of 4-(monoalkylamino) benzoic acid and derivatives and certain water-soluble materials
EP0031603A1 (en) * 1979-12-31 1981-07-08 American Cyanamid Company Pharmaceutical composition of matter

Also Published As

Publication number Publication date
PT75254A (en) 1982-08-01
US4407795A (en) 1983-10-04
IL65818A0 (en) 1982-08-31
AU8605082A (en) 1983-01-20
EP0070368A1 (en) 1983-01-26
PL237497A1 (en) 1984-09-10
DK318982A (da) 1983-01-17
ZA825069B (en) 1983-05-25
JPS5818342A (ja) 1983-02-02
PT75254B (en) 1984-07-23
ES513964A0 (es) 1983-04-16
GR76175B (es) 1984-08-03

Similar Documents

Publication Publication Date Title
ES8305212A1 (es) Procedimiento de obtencion de composiciones antiateroscleroticas.
DE3274549D1 (en) Acrylamid-copolymers suitable as thickening agent for aqueous systems and aqueous compositions containing them
IT1196553B (it) Composto di beclometasone monoidrato,composizioni che lo contengono e relativo procedimento di produzione
NO1998011I1 (no) Tiludronsyre
NL190581C (nl) 7beta-(D-2-amino-2-fenylaceetamido)-3-(propenyl)-3-cefem-4-carbonzuur verbinding en farmaceutisch preparaat dat deze verbinding omvat.
AU534447B2 (en) Hydroxyethyl-imidazoles and triazole derivatives and their use as antimycotic actents
AU555898B2 (en) Stable radiographic imaging composition
ATE21909T1 (de) Natriumsalz von ursodeoxy-cholsaeuresulfat.
ES529921A0 (es) Procedimiento para preparar composiciones adhesivas acuosas
IT8324272A0 (it) Sistema per la composizione flessibile di fasci laser.
IT7969222A0 (it) Complessi di inclusione di ciclodestrina camomilla procedimento per la loro preparazione e composizioni che li contengono
IT1158025B (it) Derivati di 3-ammino pregn-5-ene e loro sali, procedimento per la loro preparazione, per l'applicazione come medicamenti e composizioni che li contengono
MY100900A (en) Substituted phenylsulfonyloxybenzimidazolecarbamates, processes for their preparation and their use as medicaments.
IT8223942A0 (it) Complessi di inclusione di steroidi con gamma ciclodestrina,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
IT8223337A0 (it) Composizione acquosa inibitrice di corrosione e procedimento per lasua preparazione.
DE3269331D1 (en) Arene-carboxylic acid derivatives used as agents having an anti-seborrhea effect contained in cosmetic compositions
IL72731A (en) Stable antibacterial lyophilizate preparations of 7-difluoromethyl thioacetamino-7-methoxy-3-(1-(2-hydroxy lower alkyl)-1h-tetrazol-5-yl)thio-methyl-1-dethia-1-oxa-3-cephem-4-carboxylic acid alkali metal salts and methods for the production thereof
IT8147649A0 (it) Procedimento per preparare composizioni benzotriazoliche disperdibili in lubrificanti composti
AU552681B2 (en) Composition containing glycyrrhetinic acid or derivatives
PH22053A (en) Substituted tert-butanol derivative, antimycotic agents containing these compounds and use thereof
ATE6587T1 (de) Antimikrobielles praeparat.
AU3527684A (en) Succinic acid mono-dialkylamides as water-soluble corrosion inhibitors
AU557365B2 (en) Liquid residue reducing preparations containing octane-1 phosphonic acid
DK151082A (da) Fungicidt middel indeholdende triazolylderivater
AU564979B2 (en) Antimycotic agent